SSelectStock

AHCLAnlon Healthcare Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.

19.57
11.57%
74Strong

Mkt Cap
₹1,042 Cr
P/E
32.1
P/B
3.9
Div Yield
0.00%
52W High
₹20.00
52W Low
₹10.20

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,041.60
P/E32.08
P/B3.85
PEG
ROE %17.36
ROCE %16.80
Debt / Equity0.17
EPS0.61
Revenue Growth %4.00
Profit Growth %-54.80
Dividend Yield %0.00
Promoter Holding %84.67
FII Holding %0.00
DII Holding %
Beta0.59

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

BUYConviction 77%

Why buy

  • ROE: 17.4%
  • ROCE: 16.8%
  • Debt/Equity: 0.17
  • MACD: bullish
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Breakout with Volume signal (setup quality 88%)

Bull case

  • ROE: 17.4%
  • ROCE: 16.8%
  • Debt/Equity: 0.17
  • MACD: bullish

Bear case

  • Revenue growth: 4.0% YoY
  • Profit growth: -54.8% YoY
  • Volatility: 50% annualized
  • Max drawdown (1y): 36%

Key risks

  • Revenue growth: 4.0% YoY
  • Profit growth: -54.8% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹19.57
Stop Loss
₹17.52
risk 10.5%
Target 1 (1.5R)
₹22.65
+15.7%
Target 2 (3R)
₹25.73
+31.5%
Support (20d)
₹14.22
Resistance (52w)
₹20.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹2.05/share
ATR (volatility)
₹0.82
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹0.82). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental57
Technical81
Momentum99
Risk (safety)53

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78